Sanofi (SAN)-Medical Equipment-Deals and Alliances Profile

Sanofi (SAN)-Medical Equipment-Deals and Alliances Profile


  • Products Id :- GDME3811D
  • |
  • Pages: 136
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Sanofi is a healthcare company, which focuses on the research, development, manufacture and marketing a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The major products of the company include Aubagio, Lantus, Lovenox, Plavix and others. Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women's health; and vitamins, minerals and supplements. It has operations across Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

Sanofi (SAN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Sanofi, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

Sanofi, Medical Equipment Deals By Type, 2011 to YTD 2017 9

Sanofi, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

Sanofi, Medical Equipment, Deals By Market, 2011 to YTD 2017 11

Sanofi, Medical Equipment, Deals Summary, 2011 to YTD 2017 12

Sanofi, Medical Equipment, Deal Details 14

Asset Purchase 14

Sanofi Plans to Acquire Medical Device Assets 14

Venture Financing 14

Portal Instruments Raises USD25 Million in Series B Financing 14

Portal Instruments Raises USD11 Million in Series A Venture Financing 15

Partnerships 16

Abiogen Pharma Enters Into Licensing Agreement With Genzyme 16

Sanofi and Voluntis Enter into Agreement 17

Sanofi and Verily Life Sciences Form Joint Venture 17

Google Life Sciences Enters into Agreement with Sanofi 18

Veracyte Enters into Co-Promotion Agreement with Genzyme 19

Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 20

Genzyme Extends Co-Promotion Agreement with Veracyte 21

Sanofi Enters into Co-Development Agreement with Medtronic 22

Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 22

HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 23

Genzyme Enters Into Co-Marketing Agreement With Veracyte 24

Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 25

Curetis Enters Into Agreement With Sanofi Pasteur For Unyvero Platform 26

Institut Pasteur Korea Enters Into Co-Development Agreement With Sanofi-Aventis Korea 26

Voluntis and CERITD Enters Into Co-Development Agreement With Sanofi 27

Merger 28

Sanofi Japan and Genzyme Japan Merge 28

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 29

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 30

Equity Offering 31

JHL Biotech Raises USD80 Million in Private Placement of Shares 31

Alnylam Pharma to Raise USD61.5 Million in Private Placement of Shares 31

Debt Offering 33

Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 33

Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 33

Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 34

Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 35

Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 36

Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 37

Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 38

Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 39

Sanofi Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$1,000 Million 40

Asset Transactions 42

Lupin May Acquire Pulmojet from Zentiva 42

Nichi-iko Pharma To Acquire Business From Sanofi-Aventis 42

Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 43

Acquisition 45

Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 45

L'Oreal Plans To Sell Its Stake In Sanofi 45

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 46

Sanofi Completes Acquisition Of Pluromed 48

Sanofi-Aventis Completes Acquisition Of Genzyme 49

Sanofi-Key Competitors 52

Key Employees 53

Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Recent Developments 71

Strategy And Business Planning 71

Jul 05, 2016: Sanofi Enters Into Confidentiality Agreement With Medivation And Will Be Provided Due Diligence Access And Confidential Information 71

Apr 19, 2016: Sanofi Invests EUR300 Million To Expand Biologics Site in Belgium 72

Financial Announcements 73

Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 73

Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 75

Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 81

Oct 28, 2016: Sanofi Announces Strong Q3 2016 Results 88

Jul 29, 2016: Sanofi Announces Q2 2016 Results 94

Jul 29, 2016: Royalty report for Q2 2016 and update on lixisenatide (Lyxumia/Adlyxin) and iGlarLixi 101

Apr 29, 2016: Solid Performance in the First Quarter of 2016 with Business EPS up 5.3% at Constant Exchange Rates 102

Feb 09, 2016: Sanofi Delivered 2015 Business EPS Up 8.5% On A Reported Basis And Stable At Constant Exchange Rates Consistent With Guidance 108

Corporate Communications 115

Apr 12, 2017: Sanofi appoints Nikhilesh Kalra to lead Consumer Healthcare business for India and South Asia 115

Apr 11, 2017: Sanofi Announces Pre-quarterly Results Communication 116

Apr 05, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee 118

Mar 02, 2017: Sanofi's Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charles as New Independent Directors 119

Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK 120

Jan 30, 2017: Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs 121

Sep 30, 2016: Sanofi Appoints Alan Main to Executive Committee and Executive Vice President, Consumer Healthcare 122

Sep 07, 2016: Sanofi Appoints New Research Head for Immunology and Inflammation 123

Sep 06, 2016: Sanofi Board Of Directors Provides Update 124

Jun 02, 2016: Sanofi India Announces Appointment of Chairman of the Board of Directors 125

May 23, 2016: Sanofi Announces Changes to Executive Committee Aligned to its Strategic Roadmap 2020 126

Mar 29, 2016: Sanofi Appoints Dr. Yong-Jun Liu as Head of Research 127

Mar 10, 2016: Sanofi Appoints Dr. Ameet Nathwani to Executive Committee and Executive Vice President, Group Chief Medical Officer 128

Government and Public Interest 129

Jun 13, 2016: Sanofi Files Definitive Consent Solicitation To Remove And Replace Medivation's Board 129

Jun 01, 2016: Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors 130

Other Significant Developments 131

May 25, 2016: Sanofi Files Consent Solicitation To Remove and Replace Medivation's Board 131

Apr 19, 2016: Sanofi Invests EUR300 Million To Expand Biologics Site in Belgium 134

Apr 19, 2016: Sanofi Invests EUR300 Million in its Biologics Site in Belgium to Develop its Monoclonal Antibodies Portfolio 135

Appendix 136

Methodology 136

About GlobalData 136

Contact Us 136

Disclaimer 136

List of Figures

Sanofi, Medical Equipment, Deals by Type, 2011 to YTD 2017 1

Sanofi, Medical Equipment, Deals By Year, 2011 to YTD 2017 1

Sanofi, Medical Equipment, Deals By Region, 2011 to YTD 2017 1

Sanofi, Medical Equipment, Deals By Market, 2011 to YTD 2017 1

Sanofi, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

Sanofi, Medical Equipment, Deals by Type, 2011 to YTD 2017 9

Sanofi, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

Sanofi, Medical Equipment, Deals by Market, 2011 to YTD 2017 11

List of Tables

Sanofi, Medical Equipment, Key Facts, 2016 1

Sanofi, Medical Equipment, Deals Summary, 2011 to YTD 2017 1

Sanofi, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

Sanofi, Medical Equipment Deals By Type, 2011 to YTD 2017 9

Sanofi, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

Sanofi, Deals By Market, 2011 to YTD 2017 11

Sanofi, Medical Equipment, Deals Summary, 2011 to YTD 2017 12

Sanofi Plans to Acquire Medical Device Assets 14

Portal Instruments Raises USD25 Million in Series B Financing 14

Portal Instruments Raises USD11 Million in Series A Venture Financing 15

Abiogen Pharma Enters Into Licensing Agreement With Genzyme 16

Sanofi and Voluntis Enter into Agreement 17

Sanofi and Verily Life Sciences Form Joint Venture 17

Google Life Sciences Enters into Agreement with Sanofi 18

Veracyte Enters into Co-Promotion Agreement with Genzyme 19

Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 20

Genzyme Extends Co-Promotion Agreement with Veracyte 21

Sanofi Enters into Co-Development Agreement with Medtronic 22

Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 22

HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 23

Genzyme Enters Into Co-Marketing Agreement With Veracyte 24

Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 25

Curetis Enters Into Agreement With Sanofi Pasteur For Unyvero Platform 26

Institut Pasteur Korea Enters Into Co-Development Agreement With Sanofi-Aventis Korea 26

Voluntis and CERITD Enters Into Co-Development Agreement With Sanofi 27

Sanofi Japan and Genzyme Japan Merge 28

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 29

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 30

JHL Biotech Raises USD80 Million in Private Placement of Shares 31

Alnylam Pharma to Raise USD61.5 Million in Private Placement of Shares 31

Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 33

Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 33

Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 34

Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 35

Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 36

Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 37

Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 38

Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 39

Sanofi Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$1,000 Million 40

Lupin May Acquire Pulmojet from Zentiva 42

Nichi-iko Pharma To Acquire Business From Sanofi-Aventis 42

Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 43

Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 45

L'Oreal Plans To Sell Its Stake In Sanofi 45

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 46

Sanofi Completes Acquisition Of Pluromed 48

Sanofi-Aventis Completes Acquisition Of Genzyme 49

Sanofi, Key Competitors 52

Sanofi, Key Employees 53

Sanofi, Subsidiaries 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Sanofi, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16020
Site License
USD 500 INR 32040
Corporate User License
USD 750 INR 48060

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com